CMPX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compass Therapeutics Inc. (CMPX) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment at this time. While the stock has shown significant recent price momentum and has positive analyst ratings, the overbought RSI, lack of strong financial performance, and absence of Intellectia Proprietary Trading Signals suggest waiting for a better entry point.
CMPX exhibits bullish momentum with MACD positively expanding and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, RSI at 84.546 indicates the stock is overbought, suggesting a potential pullback. Key resistance levels are at R1: 6.496 and R2: 6.932, with support at S1: 5.087 and S2: 4.651.
Analysts have initiated and maintained Buy ratings with price targets of $13-$15, citing a promising pipeline and potential $1B peak sales for its lead asset, Tovecimig.
Sustained investor interest in options trading, with significant activity in $10 strike call options.
Recent price momentum with an 11.62% regular market gain.
RSI indicates overbought conditions, suggesting a potential short-term pullback.
Financial performance remains weak, with negative net income (-$15.7M) and declining EPS (-27.27% YoY).
No recent Intellectia Proprietary Trading Signals or Congress trading data to support a strong buy decision.
In Q4 2025, Compass Therapeutics reported no revenue growth (0% YoY), a net income loss of -$15.7M (up 4.54% YoY), and a decline in EPS to -0.08 (-27.27% YoY). Gross margin dropped to 0, reflecting poor financial health.
Analysts are bullish on CMPX, with Craig-Hallum and Canaccord assigning Buy ratings and price targets of $15 and $13, respectively. They highlight the company's deep pipeline, promising clinical trial results, and significant upside potential in its lead asset and early-stage pipeline.
